NASDAQ · ONCY
Oncolytics Biotech, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ONCY: Nov 11, 2026
Oncolytics Biotech, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.06. The reported EPS for the same quarter last year was $-0.1.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.06 | $-0.06 | $-0.07 | 2 |
| Dec 2026 | $-0.06 | $-0.06 | $-0.07 | 2 |
| Mar 2027 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Jun 2027 | $-0.05 | $-0.05 | $-0.05 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews- Fintel · Oct 27, 1:48 PM EDTOncolytics Biotech Inc. Reports Updated Clinical Data from Cohort 4 of GOBLET StudyOncolytics Biotech Inc. announced updated clinical data from Cohort 4 of its Phase 1/2 GOBLET study, which is evaluating pelareorep in combination with atezolizumab in patients with second-line or later squamous cell anal cancer. Although median overall survival has not yet been
- RTTNews · Oct 14, 12:21 PM EDTOncolytics Updates GOBLET Study Data Timelines, Expects Final PanCAN Grant Payment(RTTNews) – Oncolytics Biotech Inc. (ONCY), a clinical-stage immunotherapy company developing pelareorep, announced an update on its Phase 1/2 GOBLET study, including the expected timing of clinical data releases and receipt of the final payment under its grant from the Pancreati
- RTTNews · Oct 13, 4:50 AM EDTOncolytics Expands Pelareorep Patent Strategy With New Method-of-Use Filings(RTTNews) – Oncolytics Biotech Inc. (ONCY), a clinical-stage immunotherapy company, provided an update on its intellectual property strategy, highlighting progress on new method-of-use patent applications and plans to expand its portfolio with composition-of-matter protection for
- RTTNews · Sep 30, 7:33 AM EDTOncolytics Highlights Pelareorep Preclinical Findings In Hepatocellular Carcinoma(RTTNews) – Oncolytics Biotech Inc. (ONCY), a clinical-stage biotechnology company, announced that new data published in Proceedings of the National Academy of Sciences (PNAS) showed changes in the tumour microenvironment of liver cancer associated with pelareorep treatment.
- RTTNews · Sep 28, 12:25 PM EDTOncolytics Nears Interim Data Update From Randomized REO 033 Colorectal Cancer Study(RTTNews) – Oncolytics Biotech, Inc. (ONCY) announced continued clinical and operational progress in REO 033, a randomized study evaluating pelareorep in combination with FOLFIRI and bevacizumab in second-line RAS-mutant, microsatellite-stable (MSS) metastatic colorectal cancer (
- RTTNews · Sep 11, 12:06 PM EDTWeekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials(RTTNews) – Biotech and healthcare saw regulatory approvals, strategic partnerships, M&A activity, and a steady stream of clinical trial updates driving investor attention.
- RTTNews · Sep 10, 8:26 AM EDTOncolytics Biotech Reports Encouraging Pelareorep Data In Colorectal Cancer(RTTNews) – Oncolytics Biotech Inc. (ONCY) announced positive preclinical results evaluating pelareorep in combination with a pan-RAS inhibitor in a RAS-driven colorectal cancer model.
- RTTNews · Aug 18, 10:07 AM EDTOncolytics Biotech Gains FDA Alignment On Registrational Path For Colorectal Cancer Study(RTTNews) – Oncolytics Biotech Inc. (ONCY) announced that it has received written feedback from the U.S. FDA providing alignment on the registrational path for its ongoing REO 033 study of Pelareorep in second-line RAS-mutant, microsatellite stable (MSS) metastatic colorectal can
- RTTNews · Jul 21, 3:03 AM EDTOncolytics' Pelareorep Gets Fast Track Designation In Second-Line And Later Anal Cancer; Stock Down(RTTNews) – Oncolytics Biotech Inc. (ONCY), a clinical-stage immunotherapy company, announced that the U.S. Food and Drug Administration or FDA has granted Fast Track designation to Pelareorep in combination with a checkpoint inhibitor in second-Line and later Anal Cancer.
- RTTNews · Jul 13, 10:59 AM EDTOncolytics Reports Progress In REO 033 Trial, Plans FDA Meeting Ahead; Shares Jump(RTTNews) – Oncolytics Biotech Inc. (ONCY), a clinical-stage company, provided a clinical and regulatory update on REO 033, the company's study evaluating Pelareorep in combination for the second-line treatment of patients with Rat Sarcoma (RAS)-mutant, microsatellite stable (MSS
- RTTNews · Jun 17, 3:48 AM EDTOncolytics' New U.S Patent Extends Pelareorep Manufacturing Protection Into 2044(RTTNews) – Oncolytics Biotech Inc. (ONCY) has secured a new U.S. Patent that extends protection over the commercial manufacturing process of its investigational immunotherapy Pelareorep, marking another step in the company's long-term intellectual property strategy.
- RTTNews · Apr 27, 10:23 AM EDTOncolytics Aligns With FDA For Pelareorep On Pivotal Anal Cancer Study; Stock Up(RTTNews) – Oncolytics Biotech Inc. (ONCY), a clinical-stage immunotherapy company, announced that a Type C meeting with the U.S. Food and Drug Administration has resulted in alignment on the design of a pivotal clinical study of Pelareorep in patients with unresectable metastat
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Oncolytics Biotech, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.